The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that it has been selected as a finalist in the 2025 European Lifestars Awards in the category Post-IPO Raise of the Year for the European Mediterranean region.
The Lifestars Awards bring together leading figures from across the European life sciences industry, including companies, investors, and investment banks, to celebrate outstanding achievements. These annual awards recognize the individuals, teams, and organizations driving innovation, advancing healthcare solutions, and shaping the future of the sector.
The Oryzon’s nomination highlights the successful completion of a €30 million capital increase in a highly challenging market environment. The capital raise was capped at €30 million by the company’s Board of Directors. Since completion, Oryzon’s shares have consistently traded 20–25% above the placement price, underscoring investor confidence and robust aftermarket support. Winners will be announced at the in-person awards ceremony on November 17 in London.
Comments